Menu Search
Equities

Assembly Biosciences Inc

V7B:BER

Assembly Biosciences Inc

Actions
  • Price (EUR)15.75
  • Today's Change-0.40 / -2.48%
  • Shares traded100.00
  • 1 Year change+64.06%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 20:40 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Assembly Biosciences Inc grew revenues -- from 0.00 to 7.16m while net income improved from a loss of 93.09m to a smaller loss of 61.23m.
Gross margin--
Net profit margin-212.33%
Operating margin-235.24%
Return on assets-50.15%
Return on equity-101.78%
Return on investment-69.22%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Assembly Biosciences Inc fell by 32.58m. However, the company earned 22.74m from its operations for a Cash Flow Margin of 317.51%. In addition the company generated 13.82m cash from financing while 69.14m was spent on investing.
Cash flow per share-9.03
Price/Cash flow per share--
Book value per share5.47
Tangible book value per share5.47
More ▼

Balance sheet in USDView more

Assembly Biosciences Inc uses little or no debt in its capital structure.
Current ratio2.74
Quick ratio--
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.